Selective estrogen receptor modulators (SERMs):
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
New York, NY
New York Acad. of Sciences
2001
|
| Series: | Annals of the New York Academy of Sciences
949 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XIII, 390 S. Ill., graph. Darst. |
| ISBN: | 1573313580 1573313599 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV014145956 | ||
| 003 | DE-604 | ||
| 005 | 20020404 | ||
| 007 | t | ||
| 008 | 020212s2001 ad|| |||| 10||| eng d | ||
| 020 | |a 1573313580 |9 1-57331-358-0 | ||
| 020 | |a 1573313599 |9 1-57331-359-9 | ||
| 035 | |a (OCoLC)123123270 | ||
| 035 | |a (DE-599)BVBBV014145956 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-20 |a DE-12 | ||
| 050 | 0 | |a Q11 | |
| 050 | 0 | |a RM295 | |
| 082 | 0 | |a 615/.366 |2 21 | |
| 082 | 0 | |a 500 |2 21 | |
| 245 | 1 | 0 | |a Selective estrogen receptor modulators (SERMs) |c ed. by Marietta Anthony ... |
| 246 | 1 | 3 | |a SERMS |
| 264 | 1 | |a New York, NY |b New York Acad. of Sciences |c 2001 | |
| 300 | |a XIII, 390 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Annals of the New York Academy of Sciences |v 949 | |
| 650 | 4 | |a Selective estrogen receptor modulators |v Congresses | |
| 650 | 0 | 7 | |a Selektiver Östrogen-Rezeptor-Modulator |0 (DE-588)4689537-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Östrogenrezeptor |0 (DE-588)4172467-7 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 2000 |z Bethesda Md. |2 gnd-content | |
| 689 | 0 | 0 | |a Östrogenrezeptor |0 (DE-588)4172467-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Selektiver Östrogen-Rezeptor-Modulator |0 (DE-588)4689537-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Anthony, Marietta |e Sonstige |4 oth | |
| 830 | 0 | |a Annals of the New York Academy of Sciences |v 949 |w (DE-604)BV002532608 |9 949 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009694021&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-009694021 | ||
Record in the Search Index
| _version_ | 1804129018711113728 |
|---|---|
| adam_text | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Volume 949
December 2001
SELECTIVE ESTROGEN RECEPTOR
MODULATORS (SERMs)
Editors
Marietta Anthony, Barbara K. Dunn, and Sherry Sherman
This volume is the result of the NIH Workshop on Selective Estrogen Receptor Modu¬
lators (SERMs) held April 26 28, 2000 in Bethesda, Maryland.
CONTENTS
Preface. By Sherry Sherman xi
Part I. Basic Biology of SERMs
The Basic Biology of SERMs: Introduction. By Ronald Margolis 1
Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modula¬
tors: Making Sense of the Patchwork Quilt. By Neil J. McKenna and
Bert W. O Malley 3
Structure Function Relationships in Estrogen Receptors and the Characteriza¬
tion of Novel Selective Estrogen Receptor Modulators with Unique Phar¬
macological Profiles. By Benita S. Katzenellenbogen, Jun Sun,
William R. Harrington, Dennis M. Kraichely, Deshanie
Ganessunker, and John A. Katzenellenbogen 6
Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the
Quest for the Perfect SERM. By Donald P. McDonnell, Ching yi
Chang, and John D. Norris 16
Developing Animal Models for Analyzing SERM Activity. By JUDITH M.A.
Emmen and Kenneth S. Korach 36
Androgen Receptor: Structural Domains and Functional Dynamics after
Ligand Receptor Interaction. By Arun K. Roy, Rakesh K. Tyagi,
Chung S. Song, Yan Lavrovsky, Soon C. Ahn, Tae Sung Oh, and
Bandana Chatterjee 44
Tissue Specific Estrogen Biosynthesis and Metabolism. By Evan R.
Simpson, Colin Clyne, Caroline Speed, Gary Rubin, and Serdar
Bulun 58
Part II. Cancer Treatment and Prevention
Cancer Treatment and Prevention: Introduction. By Barbara K. Dunn and
Barry Kramer 68
The Past, Present, and Future of Selective Estrogen Receptor Modulation. By
V. Craig Jordan 72
Use of SERMs for the Adjuvant Therapy of Early Stage Breast Cancer. By
Antonio C. Wolff and Nancy E. Davidson 80
Breast Cancer Prevention with Selective Estrogen Receptor Modulators: A
Perspective. By Kathleen I. Pritchard 89
The Role of Tamoxifen in Breast Cancer Prevention: Issues Sparked by the
NSABP Breast Cancer Prevention Trial (P l). By Norman Wolmark
and Barbara K. Dunn 99
The Royal Marsden Hospital (RMH) Trial: Key Points and Remaining Ques¬
tions. By Trevor J. Powles 109
The Italian Breast Cancer Prevention Trial with Tamoxifen: Findings and
New Perspectives. By Aliana Guerrieri Gonzaga, Arianna Galli,
Nicole Rotmensz, and Andrea Decensi 113
A Brief Review of the International Breast Cancer Intervention Study (IBIS),
the Other Current Breast Cancer Prevention Trials, and Proposals for
Future Trials. By J. CuziCK 123
The MORE Trial—Multiple Outcomes for Raloxifene Evaluation: Breast
Cancer as a Secondary End Point—Implications for Prevention. By
Maura N. Dickler and Larry Norton 134
Quality of Life and Tamoxifen in a Breast Cancer Prevention Trial: A Sum¬
mary of Findings from the NSABP P l Study. By Richard Day 143
Part III. Cardiovascular Disease
Selective Estrogen Receptor Modulators and Cardiovascular Disease:
Introduction. By David J. Gordon 151
Cardiovascular Trials of Estrogen Replacement Therapy. By David M.
Herrington and Karen Potvin Klein 153
The Effects of Estrogen and Selective Estrogen Receptor Modulators on
Cardiovascular Risk Factors. By Brian W. Walsh 163
Selective Estrogen Receptor Modulator Effects on Serum Lipoproteins and
Vascular Function in Postmenopausal Women and in Hypercholester
olemic Men. By Arnon Blum and Richard O. Cannon, III 168
Effects of Estrogen and Selective Estrogen Receptor Modulators on
Hemostasis and Inflammation: Potential Differences among Drugs. By
Mary Cushman 175
Rationale and Overview of the Raloxifene Use for the Heart (RUTH) Trial. By
LoriMosca 181
Part IV. Osteoporosis
Prevention and Treatment of Osteoporosis: Introduction. By Saralyn Mark
and Jhumka Gupta 186
Preventing and Treating Osteoporosis: Strategies at the Millennium. By Sherry
Sherman 188
The Paradox of Small Changes in Bone Density and Reductions in Risk of
Fracture with Raloxifene. By Steven R. Cummings 198
Part IV. Cognitive Function
SERMs, Estrogen, and Cognitive Function: Introduction. By Andrew A.
Monjan 202
Effects of Hormone Replacement Therapy on Cognitive and Brain Aging.
By Susan M. Resnick and Pauline M. Maki 203
Estrogens, Selective Estrogen Receptor Modulators, and Dementia: What Is
the Evidence? By Kristine Yaffe 215
Estrogen Replacement Therapy for the Potential Treatment or Prevention of
Alzheimer s Disease. By Marilyn M. Miller, Andrew A. Monjan,
and Neil S. Buckholtz 223
Part V. Reproductive and Related Endocrine Considerations
Reproductive and Related Endocrine Considerations: Introduction. By
Estella C. Parrott 235
The Effect of SERMs on the Endometrium. By Steven R. Goldstein 237
Effect of Selective Estrogen Receptor Modulators on Reproductive Tissues
Other Than Endometrium. By Susan L. Hendrix and S. Gene
McNeeley 243
The Effect of Selective Estrogen Receptor Modulators on Parameters of the
Hypothalamic Pituitary Gonadal Axis. By Leo Plouffe, Jr. and
SURESH SlDDHANTI 25 1
Part VI. Addressing the Benefit/Risk Ratio in Taking SERMs from
Laboratory to Clinic
Translation of Basic Research—Finding the Perfect SERM: Introduction. By
Francis L. Bellino and Loretta Finnegan 259
What Would Be the Properties of an Ideal SERM? By Marietta Anthony,
J. Koudy Williams, and Barbara K. Dunn 261
Weighing the Benefits and Risks in Clinical Trials and Practice: Introduction.
By Worta McCaskill Stevens 279
Benefit/Risk Assessment of SERM Therapy: Clinical Trial versus Clinical
Practice Settings. By Joseph P. Costantino 280
The Estimation and Use of Absolute Risk for Weighing the Risks and Benefits
of Selective Estrogen Receptor Modulators for Preventing Breast Cancer.
By Mitchell H. Gail 286
SERMs, Ethnicity, and Clinical Trials: Opportunities and Challenges. By
Anne L. Taylor 292
Raloxifene: Risks and Benefits. By Elizabeth Barrett Connor 295
Defining Benefits and Risks for SERMs in Clinical Trials and Clinical
Practice. By Susan R. Johnson, Barbara K. Dunn, and Marietta
Anthony 304
Part VII. SERM Development in Industry, Academia, the NIH,
and the FDA
Roles of Industry, Government, and Academia in SERM Development:
Introduction. By Marietta Anthony and Karen Johnson 315
Developing a SERM: Stringent Preclinical Selection Criteria Leading to an
Acceptable Candidate (WAY 140424) for Clinical Evaluation. By
Barry S. Komm and C. Richard Lyttle 317
The Breast Cancer Continuum: Insights from the Tamoxifen Trials Impact
Future Drug Development Strategies. By Jerry P. Lewis 327
The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Insti¬
tute: Industry Collaborations in New Agent Development. By SHERRY S.
Ansher and Rami Scharf 333
FDA Review Practices and Priorities for Drugs Used in Cancer Treatment. By
Ken Kobayashi and Robert J. DeLap 341
Tamoxifen for the Reduction in the Incidence of Breast Cancer in Women at
High Risk for Breast Cancer. By Susan Flamm Honig 345
Negotiating Industry Sponsored Clinical Trial Agreements: A View from the
Trenches. By NlKKl J. Zapol 349
* * *
Conclusions: Considerations Regarding SERMs. By Barbara K. Dunn,
Marietta Anthony, Sherry Sherman, and Joseph P. Costantino 352
Opportunites for Future Research. By Sherry Sherman and Barbara K.
Dunn 366
Everything You Wanted to Know about SERMs
Timeline of Key Events in SERM Development 377
Estrogen Receptor Active Compounds, Estrogens, and SERMs, of Historical
and Current Interest 381
Model of Estrogen Receptor (ER) Action 382
Action of SERMs in Target Tissues 383
* * *
Glossary of Abbreviations 385
Index of Contributors 389
Financial assistance was received from:
• NATIONAL INSTITUTE ON AGING, NIH
• NATIONAL CANCER INSTITUTE/DIVISION OF CANCER
PREVENTION, NIH
• NATIONAL HEART, LUNG AND BLOOD INSTITUTE, NIH
• NATIONAL INSTITUTE OF DIABETES, DIGESTIVE AND
KIDNEY DISEASES, NIH
• NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL
AND SKIN DISEASES, NIH
• NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL
RESEARCH, NIH
• NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES,
NIH
• NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN
DEVELOPMENT, NIH
• THE NIH OFFICE OF RESEARCH ON WOMEN S HEALTH
• THE DEPARTMENT OF HEALTH AND HUMAN SERVICES/OFFICE ON
WOMEN S HEALTH
• THE AMERICAN FEDERATION FOR AGING RESEARCH
The New York Academy of Sciences believes it has a responsibility to provide an open
forum for discussion of scientific questions. The positions taken by the participants in
the reported conferences are their own and not necessarily those of the Academy. The
Academy has no intent to influence legislation by providing such forums.
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV014145956 |
| callnumber-first | Q - Science |
| callnumber-label | Q11 |
| callnumber-raw | Q11 RM295 |
| callnumber-search | Q11 RM295 |
| callnumber-sort | Q 211 |
| callnumber-subject | Q - General Science |
| ctrlnum | (OCoLC)123123270 (DE-599)BVBBV014145956 |
| dewey-full | 615/.366 500 |
| dewey-hundreds | 600 - Technology (Applied sciences) 500 - Natural sciences and mathematics |
| dewey-ones | 615 - Pharmacology and therapeutics 500 - Natural sciences and mathematics |
| dewey-raw | 615/.366 500 |
| dewey-search | 615/.366 500 |
| dewey-sort | 3615 3366 |
| dewey-tens | 610 - Medicine and health 500 - Natural sciences and mathematics |
| discipline | Allgemeine Naturwissenschaft Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01810nam a2200457 cb4500</leader><controlfield tag="001">BV014145956</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20020404 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">020212s2001 ad|| |||| 10||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1573313580</subfield><subfield code="9">1-57331-358-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1573313599</subfield><subfield code="9">1-57331-359-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)123123270</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV014145956</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">Q11</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM295</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.366</subfield><subfield code="2">21</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">500</subfield><subfield code="2">21</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Selective estrogen receptor modulators (SERMs)</subfield><subfield code="c">ed. by Marietta Anthony ...</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">SERMS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">New York Acad. of Sciences</subfield><subfield code="c">2001</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 390 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Annals of the New York Academy of Sciences</subfield><subfield code="v">949</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Selective estrogen receptor modulators</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Selektiver Östrogen-Rezeptor-Modulator</subfield><subfield code="0">(DE-588)4689537-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Östrogenrezeptor</subfield><subfield code="0">(DE-588)4172467-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">2000</subfield><subfield code="z">Bethesda Md.</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Östrogenrezeptor</subfield><subfield code="0">(DE-588)4172467-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Selektiver Östrogen-Rezeptor-Modulator</subfield><subfield code="0">(DE-588)4689537-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anthony, Marietta</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Annals of the New York Academy of Sciences</subfield><subfield code="v">949</subfield><subfield code="w">(DE-604)BV002532608</subfield><subfield code="9">949</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009694021&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009694021</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 2000 Bethesda Md. gnd-content |
| genre_facet | Konferenzschrift 2000 Bethesda Md. |
| id | DE-604.BV014145956 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:58:28Z |
| institution | BVB |
| isbn | 1573313580 1573313599 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009694021 |
| oclc_num | 123123270 |
| open_access_boolean | |
| owner | DE-20 DE-12 |
| owner_facet | DE-20 DE-12 |
| physical | XIII, 390 S. Ill., graph. Darst. |
| publishDate | 2001 |
| publishDateSearch | 2001 |
| publishDateSort | 2001 |
| publisher | New York Acad. of Sciences |
| record_format | marc |
| series | Annals of the New York Academy of Sciences |
| series2 | Annals of the New York Academy of Sciences |
| spelling | Selective estrogen receptor modulators (SERMs) ed. by Marietta Anthony ... SERMS New York, NY New York Acad. of Sciences 2001 XIII, 390 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Annals of the New York Academy of Sciences 949 Selective estrogen receptor modulators Congresses Selektiver Östrogen-Rezeptor-Modulator (DE-588)4689537-1 gnd rswk-swf Östrogenrezeptor (DE-588)4172467-7 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 2000 Bethesda Md. gnd-content Östrogenrezeptor (DE-588)4172467-7 s DE-604 Selektiver Östrogen-Rezeptor-Modulator (DE-588)4689537-1 s Anthony, Marietta Sonstige oth Annals of the New York Academy of Sciences 949 (DE-604)BV002532608 949 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009694021&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Selective estrogen receptor modulators (SERMs) Annals of the New York Academy of Sciences Selective estrogen receptor modulators Congresses Selektiver Östrogen-Rezeptor-Modulator (DE-588)4689537-1 gnd Östrogenrezeptor (DE-588)4172467-7 gnd |
| subject_GND | (DE-588)4689537-1 (DE-588)4172467-7 (DE-588)1071861417 |
| title | Selective estrogen receptor modulators (SERMs) |
| title_alt | SERMS |
| title_auth | Selective estrogen receptor modulators (SERMs) |
| title_exact_search | Selective estrogen receptor modulators (SERMs) |
| title_full | Selective estrogen receptor modulators (SERMs) ed. by Marietta Anthony ... |
| title_fullStr | Selective estrogen receptor modulators (SERMs) ed. by Marietta Anthony ... |
| title_full_unstemmed | Selective estrogen receptor modulators (SERMs) ed. by Marietta Anthony ... |
| title_short | Selective estrogen receptor modulators (SERMs) |
| title_sort | selective estrogen receptor modulators serms |
| topic | Selective estrogen receptor modulators Congresses Selektiver Östrogen-Rezeptor-Modulator (DE-588)4689537-1 gnd Östrogenrezeptor (DE-588)4172467-7 gnd |
| topic_facet | Selective estrogen receptor modulators Congresses Selektiver Östrogen-Rezeptor-Modulator Östrogenrezeptor Konferenzschrift 2000 Bethesda Md. |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009694021&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002532608 |
| work_keys_str_mv | AT anthonymarietta selectiveestrogenreceptormodulatorsserms AT anthonymarietta serms |